Stock Scorecard



Stock Summary for Centessa Pharmaceuticals plc (CNTA) - $16.83 as of 11/20/2024 3:54:09 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CNTA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CNTA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CNTA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CNTA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CNTA (25 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0

Latest News for for CNTA

Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 ( OX2R ) Agonist 11/13/2024 12:01:00 AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences 11/4/2024 12:30:00 PM
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist, at the 27th Congress of the European Sleep Research Society ( Sleep Europe 2024 ) 9/26/2024 10:00:00 AM
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist, at the 27th Congress of the European Sleep Research Society ( Sleep Europe 2024 ) - Centessa Pharmaceuticals ( NASDAQ:CNTA ) 9/26/2024 10:00:00 AM
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist, at the 27th Congress of the European Sleep Research Society ( Sleep Europe 2024 ) 9/26/2024 10:00:00 AM
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares - Centessa Pharmaceuticals ( NASDAQ:CNTA ) 9/13/2024 2:34:00 AM
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 ( OX2R ) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers 9/11/2024 10:52:00 AM
Why Is Sleep-Disorder Focused Centessa Pharmaceuticals Stock Trading Higher On Tuesday? - Centessa Pharmaceuticals ( NASDAQ:CNTA ) 9/10/2024 4:19:00 PM
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday - Calavo Growers ( NASDAQ:CVGW ) 9/10/2024 2:07:00 PM
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 ( OX2R ) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers 9/10/2024 11:00:00 AM

Financial Details for CNTA

Company Overview

Ticker CNTA
Company Name Centessa Pharmaceuticals plc
Country USA
Description Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers drugs that change and improve the lives of patients. The company is headquartered in Cambridge, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 16.83
Price 4 Years Ago 0.00
Last Day Price Updated 11/20/2024 3:54:09 PM EST
Last Day Volume 591,844
Average Daily Volume 434,407
52-Week High 18.74
52-Week Low 5.58
Last Price to 52 Week Low 201.61%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -6.56
Free Cash Flow Ratio 4.28
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 21.52
Total Cash Per Share 3.93
Book Value Per Share Most Recent Quarter 4.29
Price to Book Ratio 4.45
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 323.79
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 131,845,000
Market Capitalization 2,218,951,350
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 30.12%
Reported EPS 12 Trailing Months -1.52
Reported EPS Past Year -1.15
Reported EPS Prior Year -1.57
Net Income Twelve Trailing Months -161,265,000
Net Income Past Year -151,085,000
Net Income Prior Year -216,207,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -23.59

Balance Sheet

Total Cash Most Recent Quarter 518,449,000
Total Cash Past Year 256,549,000
Total Cash Prior Year 393,644,000
Net Cash Position Most Recent Quarter 441,949,000
Net Cash Position Past Year 180,849,000
Long Term Debt Past Year 75,700,000
Long Term Debt Prior Year 69,800,000
Total Debt Most Recent Quarter 76,500,000
Equity to Debt Ratio Past Year 0.76
Equity to Debt Ratio Most Recent Quarter 0.87
Total Stockholder Equity Past Year 236,244,000
Total Stockholder Equity Prior Year 336,169,000
Total Stockholder Equity Most Recent Quarter 499,137,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -130,367,000
Free Cash Flow Per Share Twelve Trailing Months -0.99
Free Cash Flow Past Year -160,511,000
Free Cash Flow Prior Year -201,683,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.36
MACD Signal 0.28
20-Day Bollinger Lower Band 9.04
20-Day Bollinger Middle Band 14.07
20-Day Bollinger Upper Band 19.11
Beta 1.48
RSI 45.87
50-Day SMA 11.07
150-Day SMA 7.44
200-Day SMA 0.00

System

Modified 11/20/2024 9:43:26 PM EST